Emergen Research has developed this content with a clear objective—to provide businesses with actionable insights rather than just theoretical data. The Biologics Drug Discovery market research content is prepared using a mix of primary and secondary research methods, ensuring accuracy and reliability. It includes detailed reports, industry-specific case studies, whitepapers, and trend analyses that cover sectors such as healthcare, technology, finance, manufacturing, and consumer goods.
The global Biologics Drug Discovery market size is expected to grow from 471.9 billion by the end of 2025 to 1008.1 billion by 2035, registering a revenue CAGR of 8.80% during the forecast period. The major biologics drug discovery market growth factors are adoption of AI-driven antibody design platforms, expansion of synthetic biology in biologic engineering, and technology advancements. The Biologics Drug Discovery market driven by increasing demand for targeted therapies that offer more effective and personalized treatments is propelling the market growth.
Biologics, including monoclonal antibodies, gene therapies, and cell-based therapies, have shown promise in treating a wide range of chronic and complex diseases such as cancer, autoimmune disorders, and genetic conditions. These therapies offer significant advantages over traditional small molecule drugs by targeting specific molecules involved in disease progression, leading to higher efficacy and fewer side effects.
The growing focus on precision medicine, along with advancements in genomics and biotechnology, is driving the demand for biologics, creating a favorable market environment for their discovery and development. For instance, in August 2022, Sanofi partnered with Atomwise in a drug design deal worth potentially up to USD 1.2 billion. The contract, for which Sanofi paid USD 20 million upfront, focused on using the AtomNet platform to research small molecules for up to five drug targets selected by Sanofi.
Additionally, advancements in technology, such as CRISPR gene editing, artificial intelligence (AI), and high-throughput screening, are accelerating the biologics drug discovery process. These technologies enable more efficient identification of novel drug targets, optimization of biologic candidates, and faster clinical trials. AI, in particular, plays a key role in predicting the behavior of biologic molecules, speeding up the drug development timeline and reducing costs.
With increased investment in research and development (R&D) from both public and private sectors, these innovations are fueling market growth, enabling companies to discover new biologic drugs with greater precision and speed. For instance, in February 2025, Variational AI, a Canada-based software company, successfully raised USD 5.5 million in an oversubscribed seed extension round.
competitive landscape:-
Understanding the competitive environment is often the first step toward building a strong business strategy. The latest Biologics Drug Discovery market research content introduced by Emergen Research places significant emphasis on this aspect by offering a detailed overview of the competitive landscape. The report highlights key companies, their strategic initiatives, and their position in the global market, helping businesses gain clarity about where they stand in comparison.
Adoption of AI-Driven Antibody Design Platforms drives market growth
The adoption of AI-driven antibody design platforms is driving the biologics drug discovery market by significantly improving the efficiency and accuracy of the antibody development process. Traditional antibody discovery can be time-consuming and resource-intensive, often requiring extensive trial and error in laboratory settings. AI-powered platforms, however, utilize machine learning algorithms and vast biological data sets to predict the most effective antibody candidates.
These platforms can identify optimal binding sites, predict immune responses, and fine-tune antibodies for specific targets, thus accelerating the discovery process. This reduces the time from concept to clinical trials, enabling faster delivery of new biologic therapies to the market and increasing the overall productivity of drug discovery efforts. For instance, in September 2022, a report by the WHO stated that about 55 million people worldwide are living with dementia, and nearly 10 million cases are reported annually.
Furthermore, AI-driven platforms are enhancing the precision of antibody design, allowing for the creation of more targeted and effective therapies. By integrating data from genomics, proteomics, and clinical studies, AI can better understand the complexities of diseases and immune systems.
This helps in designing antibodies that are not only more potent but also more specific, reducing the risk of off-target effects and improving safety profiles. As the demand for personalized medicine continues to rise, these AI platforms are playing a critical role in developing biologic therapies tailored to individual patients, further fueling the growth of the biologics drug discovery market.
Along with analyzing competitors, the report dives deep into market dynamics, providing a clear understanding of how the Biologics Drug Discovery market is evolving. It identifies key growth drivers, emerging opportunities, and potential challenges that businesses may encounter. This makes the research highly useful not only for large enterprises but also for startups and investors looking to explore new possibilities.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4927
Market segmentation:-
Another strong feature of this report is its detailed market segmentation. By dividing the market into categories based on product type, application, end-user, and region, the research allows businesses to identify which areas offer the most potential. This level of detail helps organizations create targeted strategies and optimize their investments.
The competitive landscape of the biologics drug discovery market is characterized by the presence of large pharmaceutical companies, biotech firms, contract development and manufacturing organizations (CDMOs), and specialized technology providers. Key players such as Pfizer, Roche, Amgen, and Eli Lilly dominate the market with their extensive portfolios of biologic drugs and ongoing research initiatives.
These companies focus on innovations in monoclonal antibodies, gene therapies, and cell-based therapies. Additionally, smaller biotech firms are increasingly playing a role by partnering with large corporations to bring novel biologic drugs to market. Outsourcing to CDMOs is common, as it allows biotech companies to focus on R&D while leveraging the expertise of established manufacturing partners. Technological advancements, particularly in AI and gene-editing tools like CRISPR, also shape competition in this space.
In March 2025, Biogen Inc. received approval from the US Food and Drug Administration (FDA) for TOFIDENCE (tocilizumab-bavi) intravenous formulation. TOFIDENCE marks the pioneering approval of the tocilizumab biosimilar in the United States, signaling a significant advancement in treatment options for specified medical conditions.
Biologics Drug Discovery Market Leaders
- Amgen
- Merck & Co.
- Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb
- Sanofi
- Bayer AG
- AstraZeneca
- GlaxoSmithKline Plc.
- Novartis AG
- Eli Lilly and Company
In addition to segmentation, the report provides valuable recommendations that businesses can implement directly. These insights are designed to improve operational efficiency, enhance customer engagement, and support long-term growth. Instead of overwhelming readers with complex data, the content simplifies information and makes it easy to understand.
Key features and benefits of Emergen Research’s market research content include:
- Comprehensive Analysis: Each piece of content is meticulously researched and provides a detailed analysis of market trends, competitive landscape, consumer behavior, and emerging opportunities. Businesses can leverage this information to identify untapped markets, devise effective marketing strategies, and make data-driven decisions.
- Actionable Recommendations: The market research content provides practical insights and actionable recommendations to help businesses enhance their products, services, and overall customer experience. These recommendations are tailored to the specific needs and challenges of each industry, allowing companies to implement strategies that drive growth and profitability.
- Expert Insights: Emergen Research’s team of industry experts and analysts contribute their in-depth knowledge and expertise to every piece of content. Their insights shed light on industry-specific challenges, best practices, and emerging trends, helping businesses stay ahead of the competition and seize new opportunities.
- Timely Updates: The market research content is regularly updated to reflect the latest market trends and dynamics. Subscribers will have access to the most up-to-date information, enabling them to adapt their strategies and stay relevant in today’s rapidly evolving business environment.
-
Type Outlook (Revenue, USD Billion, 2021–2034)
- Blood and Blood Products
- Cellular and Gene Therapy Products
- Tissue and Tissue Products
- Vaccines
- Others Types
-
Indication Outlook (Revenue, USD Billion, 2021–2034)
- Oncology
- Immunology
- Infectiuos Disease
- Other Indications
-
Application Outlook (Revenue, USD Billion, 2021–2034)
- Diagnosis
- Treatment
-
Manufacturing Facility Outlook (Revenue, USD Billion, 2021–2034)
- Outsourced
- In-house
-
Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
- North America
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4927
Emergen Research also ensures that its research remains relevant by updating it regularly. In today’s fast-changing business environment, having access to the latest information is crucial. Companies that stay updated are better positioned to respond quickly to changes and maintain a competitive edge.
The report caters to a wide audience, including investors, businesses of all sizes, consultants, and policymakers. Each group can use the insights in different ways, whether it’s for investment decisions, market entry strategies, or policy development.
One of the key strengths of this research content is the expertise behind it. The analysts at Emergen Research bring years of experience and industry knowledge, ensuring that every report delivers meaningful insights. Their ability to interpret data and identify trends adds significant value to the content.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/biologics-drug-discovery-market
About Emergen Research
Emergen Research is a globally recognized market research and consulting firm known for its data-driven insights and strategic solutions. The company provides syndicated reports, customized research, and consulting services to help businesses understand market trends and achieve their goals.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com